Search clinical trials for: Men at intermediate risk of prostate cancer

Total 465922 results

Abramson Cancer Center at Penn Medicine

Active, not recruiting

Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer

Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Anal Canal Cloacogenic Carcinoma | Stage III Anal Cancer AJCC v8 | Anal Margin Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Anal Basaloid Squamous Cell Carcinoma

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Cancer AJCC v8 | Stage II Uterine Corpus Cancer AJCC v8

United States, Puerto Rico
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Turkey, Mexico, Belgium, Korea, Republic of, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece
Memorial Sloan Kettering Cancer Center
Icahn School of Medicine at Mount Sinai

Active, not recruiting

Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies

Low Risk Prostate Cancer

United States
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)

Prostatic Neoplasms

United States, Italy, Czechia, Israel, Japan, Taiwan, Korea, Republic of, United Kingdom, France, Spain, Germany, Australia, Canada, Brazil, Netherlands, Russian Federation, Argentina, Poland
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
MacroGenics

Active, not recruiting

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Umeå University

Completed

Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer (PARAPLY-1)

Prostatic Neoplasms | Lymphatic Metastasis

Sweden
Hospices Civils de Lyon

Active, not recruiting

Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer (FOCALE)

Prostate Cancer

France, Sweden
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Mucosal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
NRG Oncology
National Cancer Institute (NCI)

Suspended

Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer (NADIR)

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

Canada, United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
Thomas Jefferson University

Suspended

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Astellas Pharma Inc; Medivation, Inc.

Active, not recruiting

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Recurrent Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIB Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Active, not recruiting

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Prostate

United States
Canadian Cancer Trials Group

Completed

Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer

Prostate Cancer

Canada
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Validation Study on the Impact of Decipher® Testing - VANDAAM Study (VANDAAM)

Prostate Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Prostate Carcinoma

United States
Assistance Publique Hopitaux De Marseille

Completed

Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer (SENTINELLE)

Patient With Prostate Cancer

France
Accuray Incorporated

Completed

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

Prostatic Neoplasms | Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Prostatic Cancer

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Prostate Cancer

United States, Canada
Rete Oncologica Piemonte, Valle d'Aosta
Azienda Ospedaliera Città della Salute e della Scienza di Torino; Compagnia...

Completed

Active Surveillance or Radical Treatment for Newly Diagnosed Patients With a Localized, Low Risk, Prostate Cancer START (START)

Prostatic Neoplasm

Italy
H. Lee Moffitt Cancer Center and Research Institute

Completed

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

Prostate Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer (PALS)

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC V7 | Stage IIA Prostate Cancer AJCC v7

United States
M.D. Anderson Cancer Center
MDS Clinical Research Consortium

Completed

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Leukemia

United States
Angiodynamics, Inc.

Active, not recruiting

Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

Prostate Cancer

United States
Bayer

Completed

A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe (Safe-CAM)

Prostate Cancer | Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea | Hypersexuality in Men | Sexual Deviations in Men

Spain, Germany, Netherlands, Poland, France
Celgene
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme...

Completed

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST)

Myelodysplastic Syndromes

Canada, United States, Germany, Belgium, France, United Kingdom, Turkey, Spain, Italy, Netherlands, Sweden
University of Utah
Genentech, Inc.; Bavarian Nordic

Withdrawn

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)

Prostate Adenocarcinoma

United States
Genomic Health®, Inc.

Completed

Study In Urology Practices Looking At Impact Of OncotypeDX GPS Test On Men Choosing And Remaining On Active Surveillance

Prostate Cancer
Steba Biotech S.A.
International Drug Development Institute; PrimeVigilance LTD

Terminated

Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer

Low Risk Prostate Cancer

France
Association of Urologic Oncology (AUO)

Terminated

Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk (PREFERE)

Prostate Cancer

Germany
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States
University of Texas Southwestern Medical Center

Terminated

Circulating Tumor Cells in Prostate Cancer Patients

Prostate Cancer

United States
University of California, San Francisco

Completed

Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model

Prostate Cancer

United States
Juravinski Cancer Center
Sanofi

Unknown

Prostate Boost Irradiation With Stereotactic Body RT (SBRT) (PBS)

Prostate Cancer

Canada
Abramson Cancer Center of the University of Pennsylvania

Completed

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

Prostate Adenocarcinoma

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Bavarian Nordic

Completed

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)

Prostate Cancer Metastatic

United States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca

Completed

Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy (CaNCaP03)

Prostate Cancer

United Kingdom
RPCR, Inc.

Unknown

Multi-Institutional Registry for Prostate Cancer Radiosurgery (RPCR)

Prostate Cancer Early Risk Treated by Radiosurgery | Prostate Cancer Intermediate Risk Treated by Radiosurgery

United States
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca

Completed

Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer (CaNCaP02)

Prostate Cancer

United Kingdom
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

Prostate Cancer

United States, Canada
Molecular Insight Pharmaceuticals, Inc.

Completed

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer (proSPECT-AS)

Prostate Cancer

United States, Canada

Search clinical trials for: Men at intermediate risk of prostate cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations